Show Summary Details
Page of

The role of biologicals in the treatment of lupus nephritis 

The role of biologicals in the treatment of lupus nephritis
The role of biologicals in the treatment of lupus nephritis

Amara N. Ezeonyeji

and David A. Isenberg

Page of

PRINTED FROM OXFORD MEDICINE ONLINE ( © Oxford University Press, 2020. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 23 September 2020

1. Over the last few years, treatment of SLE and LN has moved from serendipity to immunological sense focusing on biological agents that target the cells and molecules specifically involved in the critical pathways in SLE pathogenesis.

2. Biological agents offer the possibility of efficacious and safe treatment options for patients with refractory disease, reducing the burden of immunosuppressive drugs.

3. In spite of some recent disappointing results with biological, including abatacept and rituximab, a number of newer agents have shown encouraging benefits.

4. Belumimab and epratuzumab have both met their primary end-points in the BLISS-52, BLISS-76 and epratuzumab phase IIb trials, and rontalizumab and tociluzumab have shown promising results in phase I studies.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.